How Long Does It Take for Allergy Shots to Work? Month-by-Month Timeline

Most patients notice their first meaningful symptom improvement within 3 to 6 months of starting allergy shots, though some require up to 12 months before detecting clear benefit. This timeline reflects real immunological milestones: IgG4 blocking antibodies begin rising at 1 to 3 months and reach significant levels by 3 to 6 months, while regulatory T cells become detectable within 2 to 4 weeks. The 2007 Cochrane review of 51 randomized controlled trials found a pooled symptom score reduction of -0.73 SMD, achieved largely within the first year of reaching maintenance dose. Patients who feel no improvement by 6 months should continue — the biological process is ongoing even when symptoms have not yet changed.

Yes, the majority of patients who respond to allergy shots experience meaningful improvement within the first year of maintenance dosing. The AAAAI/ACAAI Practice Parameter (Cox et al., JACI 2011) states that clinical improvement is usually observed within 1 year of reaching the maintenance dose. However, the first year of treatment often includes the build-up phase, during which almost no symptom relief is expected. Meaningful improvement is measured from when the maintenance dose is first reached — typically 3 to 6 months into treatment. Between 50 and 80 percent of patients in observational cohorts achieve clinically meaningful improvement by the end of the first year of maintenance, though individual responses vary significantly.

Allergy shots trigger a coordinated immune tolerance cascade that unfolds in stages. Within the first 6 hours of a build-up injection, basophils upregulate histamine H2 receptors, suppressing IgE-triggered degranulation. Within 2 to 4 weeks, FOXP3+ regulatory T cells and IL-10-producing regulatory B cells become detectable. Between 1 and 3 months, allergen-specific IgG4 blocking antibodies begin rising measurably. By 3 to 12 months, IgG4 reaches 10 to 100 times baseline levels, competitively binding allergen and preventing IgE from triggering mast cells. Over years 1 to 3, tissue eosinophil and mast cell counts fall in mucosal tissues, Th2 cytokines (IL-4, IL-5, IL-13) decline, and a stable regulatory immune environment is established. This multi-year cascade is what makes allergy shots disease-modifying rather than just symptom-suppressing.

Patients who complete the full 3 to 5 year maintenance course typically retain clinically meaningful benefits for 3 to 12 years after stopping allergy shots. Durham et al. (New England Journal of Medicine, 1999) demonstrated that symptom and medication scores remained as low as during active maintenance for at least 3 years post-discontinuation after a 3 to 4 year grass pollen SCIT course. Eng et al. (Allergy, 2006) followed the same cohort for 12 years and found total hayfever symptom scores still significantly lower than untreated controls, though skin reactivity had partially returned. In children from the PAT study, the benefit of reduced asthma development persisted 7 years after treatment stopped, with 25 percent of treated children developing asthma versus 45 percent of controls at the 10-year follow-up.

Six months is often still within the build-up phase or the very early maintenance period — this is biologically normal and does not indicate treatment failure. IgG4 levels may have just started rising meaningfully, and the immune system requires sustained allergen exposure to build sufficient blocking antibody concentrations. Factors that can delay benefit include being polysensitized to multiple allergens, not yet having reached the full target maintenance dose, missed injections requiring dose reductions, or concurrent medications that mask early improvements. The AAAAI/ACAAI Practice Parameter recommends a formal non-responder evaluation only after 1 full year of maintenance dosing. If you feel no improvement at that point, your allergist should reassess the allergen formulation, dose, and diagnosis accuracy before considering discontinuation.

Cluster and rush immunotherapy protocols can compress the build-up phase from 8 to 28 weeks down to 4 to 8 weeks (cluster) or 1 to 3 days (rush), meaning patients reach the therapeutic maintenance dose earlier — potentially allowing first improvement sooner. However, the maintenance phase duration remains 3 to 5 years regardless of build-up speed. Rush protocols carry approximately 3 times the per-injection systemic reaction rate of conventional schedules and require premedication. Certain allergen categories also respond faster: venom immunotherapy (for bee or wasp stings) achieves 95 to 98 percent protection and is clinically evident much sooner than inhalant SCIT. Grass pollen-sensitized patients may notice improvement within their first treated pollen season if they reach maintenance before peak exposure.

Allergy shots are not permanent in an absolute sense, but they are the only allergy treatment proven to produce lasting disease modification that continues after treatment stops. Patients who complete 3 to 5 years of maintenance therapy typically experience 3 to 12 years of sustained benefit post-treatment, with some evidence of continued partial benefit even longer. Eng et al. (Allergy, 2006) found meaningful clinical benefit persisting 12 years after a childhood grass SCIT course, though skin test reactivity had partially returned by that point, suggesting gradual immunological waning without full clinical relapse. For some patients, especially those with severe or multiple allergies, additional maintenance injections or a second course may be considered if symptoms return years later.